Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Paratek Pharmaceuticals Inc    PRTK

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/05/2017 12/06/2017 12/07/2017 12/08/2017 12/11/2017 Date
17.95(c) 17.65(c) 17.65(c) 17.45(c) 17.65(c) Last
234 607 245 148 346 995 595 031 297 809 Volume
-3.23% -1.67% 0.00% -1.13% +1.15% Change
More quotes
Financials ($)
Sales 2017 10,1 M
EBIT 2017 -85,4 M
Net income 2017 -88,7 M
Finance 2017 95,3 M
Yield 2017 -
Sales 2018 14,6 M
EBIT 2018 -94,5 M
Net income 2018 -98,2 M
Finance 2018 109 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 39,5x
EV / Sales2018 26,3x
Capitalization 493 M
More Financials
Company
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry.Its products include Omadacycline and Sarecycline.The company was founded in February 2001 and is... 
More about the company
Surperformance© ratings of Paratek Pharmaceuticals In
Trading Rating : Investor Rating :
More Ratings
Latest news on PARATEK PHARMACEUTICALS IN
12/05 PARATEK PHARMACEUTICALS : Announces Inducement Grants under NASDAQ Listing Rule ..
12/01 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
11/17 PARATEK PHARMACEUTICALS : MMS Selected by Paratek to Support its NDA Submissions..
11/08 PARATEK PHARMACEUTICALS : reports 3Q loss
11/08 Paratek Pharmaceuticals Reports Third Quarter 2017 Financial Results, Remains..
11/08 PARATEK PHARMACEUTICALS INC : to Host Earnings Call
11/08 PARATEK PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
11/07 PARATEK PHARMACEUTICALS : Announces Inducement Grants under NASDAQ Listing Rule ..
11/01 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
10/27 PARATEK PHARMACEUTICALS : to Report Third Quarter 2017 Financial Results and Pro..
More news
Sector news : Bio Therapeutic Drugs
10:43a M&A dominates Europe share trading as oil leads gains
12/09 Tax-loss selling to pressure 2017's losers in December
11/30 GENMAB : and J&J 'love' partnership as some ponder takeover
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12/01 Planned equity offering roundup - healthcare
11/14 Tracking Seth Klarman's Baupost Group Holdings - Q3 2017 Update
11/08 Paratek Pharmaceuticals' (PRTK) CEO Michael Bigham on Q3 2017 Results - Earni..
11/08 Paratek Pharmaceuticals reports Q3 results
10/25 Paratek For The Layman
Chart PARATEK PHARMACEUTICALS IN
Duration : Period :
Paratek Pharmaceuticals In Technical Analysis Chart | PRTK | US6993743029 | 4-Traders
Technical analysis trends PARATEK PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Average target price 41,6 $
Spread / Average Target 135%
EPS Revisions
Managers
NameTitle
Michael F. Bigham Chairman & Chief Executive Officer
Evan Loh President, COO, Director & CMO
Douglas W. Pagán Chief Financial & Accounting Officer
Paul McGovern Vice President-Clinical & Medical Affairs
Thomas John Dietz Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PARATEK PHARMACEUTICALS INC14.61%493
GILEAD SCIENCES1.55%99 094
REGENERON PHARMACEUTICALS1.78%40 969
VERTEX PHARMACEUTICALS88.38%35 831
GENMAB1.79%11 452
BLUEBIRD BIO INC172.12%9 249